1.93
0.04 (2.17%)
| Penutupan Terdahulu | 1.89 |
| Buka | 1.89 |
| Jumlah Dagangan | 408,504 |
| Purata Dagangan (3B) | 1,388,709 |
| Modal Pasaran | 93,282,552 |
| Harga / Pendapatan (P/E Ke hadapan) | 151.52 |
| Harga / Buku (P/B) | 1.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| EPS Cair (TTM) | -1.59 |
| Nisbah Semasa (MRQ) | 9.08 |
| Aliran Tunai Operasi (OCF TTM) | -109.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -124.32 M |
| Pulangan Atas Aset (ROA TTM) | -59.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -70.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cassava Sciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.33 |
|
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.79% |
| % Dimiliki oleh Institusi | 32.98% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |